checkAd
    Startseite > Aktien > Aurinia Pharmaceuticals > Nachrichten
    Aurinia Pharmaceuticals Aktie
    4,8940
     
    EUR
    -2,55 %
    -0,1280 EUR
    Letzter Kurs 08:49:20 Tradegate
    4,9010
     
    EUR
    480 STK
    Geldkurs 13:07:21
    5,0020
     
    EUR
    600 STK
    Briefkurs 13:07:21
    ISIN: CA05156V1022 · WKN: A1W7D4 · SYM: IKAP · Kanada

    Neueste Nachrichten

    Aurinia Presents Safety and Efficacy Profile of LUPKYNIS for People with Lupus Nephritis at European Alliance of Associations for Rheumatology (EULAR) Congress 2024
    05.06.24 · Business Wire (engl.) · Aurinia Pharmaceuticals
    Aurinia Addresses Dubious Proposals Put Forth by Lucien Selce
    04.06.24 · Business Wire (engl.) · Aurinia Pharmaceuticals
    Aurinia Provides Update on Proxy Statement
    04.06.24 · Business Wire (engl.) · Aurinia Pharmaceuticals
    Aurinia Will Attend 2024 Jefferies Global Healthcare Conference
    30.05.24 · Business Wire (engl.) · Aurinia Pharmaceuticals
    Analysis Showing LUPKYNIS is a Cost-Effective Treatment for Lupus Nephritis Presented at National Kidney Foundation’s Spring Clinical Meeting 2024
    14.05.24 · Business Wire (engl.) · Aurinia Pharmaceuticals
    Aurinia Presents Data Reinforcing LUPKYNIS Safety and Efficacy for People with Lupus Nephritis at Congress of Clinical Rheumatology East 2024
    09.05.24 · Business Wire (engl.) · Aurinia Pharmaceuticals
    Aurinia Will Attend 2024 RBC Capital Markets Global Healthcare Conference
    07.05.24 · Business Wire (engl.) · Aurinia Pharmaceuticals
    Aurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational Results
    02.05.24 · Business Wire (engl.) · Aurinia Pharmaceuticals
    Aurinia Underscores Enduring Commitment to People Living with Lupus Nephritis Through Innovative Advocacy and Education Initiatives for Lupus Awareness Month
    01.05.24 · Business Wire (engl.) · Aurinia Pharmaceuticals
    The U.S. Food & Drug Administration (FDA) Approves Updated LUPKYNIS (voclosporin) Label to include Long-Term Data from the AURORA Clinical Program
    30.04.24 · Business Wire (engl.) · Aurinia Pharmaceuticals
    UPDATE: New Aurinia Presentation Details at the 2024 Bloom Burton & Co. Healthcare Investor Conference
    16.04.24 · Business Wire (engl.) · Aurinia Pharmaceuticals
    Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 2, 2024
    15.04.24 · Business Wire (engl.) · Aurinia Pharmaceuticals